eFFECTOR Therapeutics, Inc. (EFTR)
(Delayed Data from OTC)
$0.03 USD
-0.01 (-27.71%)
Updated Oct 4, 2024 03:40 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
EFTR 0.03 -0.01(-27.71%)
Will EFTR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for EFTR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EFTR
eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails
Does eFFECTOR Therapeutics, Inc. (EFTR) Have the Potential to Rally 814.53% as Wall Street Analysts Expect?
EFTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi
Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug